BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34687671)

  • 1. A novel biphenyl diester derivative, AB38b, inhibits glioblastoma cell growth via the ROS-AKT/mTOR pathway.
    Meng Q; Zhou J; You F; Wu Y; Yang L; Wang Y; Zhang X; Gao S; Yu R; Yin X
    Biochem Pharmacol; 2021 Dec; 194():114795. PubMed ID: 34687671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule Molephantin induces apoptosis and mitophagy flux blockage through ROS production in glioblastoma.
    Ling Z; Pan J; Zhang Z; Chen G; Geng J; Lin Q; Zhang T; Cao S; Chen C; Lin J; Yuan H; Ding W; Xiao F; Xu X; Li F; Wang G; Zhang Y; Li J
    Cancer Lett; 2024 Jun; 592():216927. PubMed ID: 38697460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
    Fu J; Zhu SH; Xu HB; Xu YQ; Wang X; Wang J; Kong PS
    J Ethnopharmacol; 2020 Oct; 261():113071. PubMed ID: 32603676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway.
    Li Z; Chen Y; An T; Liu P; Zhu J; Yang H; Zhang W; Dong T; Jiang J; Zhang Y; Jiang M; Yang X
    J Exp Clin Cancer Res; 2019 Mar; 38(1):139. PubMed ID: 30922391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
    Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
    Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells.
    Koul N; Sharma V; Dixit D; Ghosh S; Sen E
    BMC Cancer; 2010 Jun; 10():328. PubMed ID: 20576128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling.
    Atif F; Yousuf S; Stein DG
    J Steroid Biochem Mol Biol; 2015 Feb; 146():62-73. PubMed ID: 24787660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway.
    Cheng Y; Xie P
    J Biochem Mol Toxicol; 2019 Nov; 33(11):e22392. PubMed ID: 31503386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
    Yuan Y; Xue X; Guo RB; Sun XL; Hu G
    CNS Neurosci Ther; 2012 Jul; 18(7):536-46. PubMed ID: 22530672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Punicic Acid Inhibits Glioblastoma Migration and Proliferation via the PI3K/AKT1/mTOR Signaling Pathway.
    Mete M; Ünsal ÜÜ; Aydemir I; Sönmez PK; Tuglu MI
    Anticancer Agents Med Chem; 2019; 19(9):1120-1131. PubMed ID: 30950355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis.
    Gao D; Nyalali AMK; Hou Y; Xu Y; Zhou J; Zhao W; Huang B; Li F
    J Mol Neurosci; 2021 Aug; 71(8):1703-1713. PubMed ID: 33400072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma.
    Li Q; Liu X; Mao J; Liu S; Hou B; Li K; Fang D
    Biochem Biophys Res Commun; 2023 Oct; 676():149-157. PubMed ID: 37517217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinomenine Hydrochloride Inhibits Human Glioblastoma Cell Growth through Reactive Oxygen Species Generation and Autophagy-Lysosome Pathway Activation: An In Vitro and In Vivo Study.
    Jiang Y; Jiao Y; Wang Z; Li T; Liu Y; Li Y; Zhao X; Wang D
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28891980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
    Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
    Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
    J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.